Total Payments
$1.1M
2024 Payments
$2,240
Companies
13
Transactions
74
Medicare Patients
512
Medicare Billing
$27,680
Payment Breakdown by Category
Research$969,893 (88.0%)
Consulting$97,166 (8.8%)
Other$33,144 (3.0%)
Travel$815.66 (0.1%)
Food & Beverage$752.13 (0.1%)
Education$45.81 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $969,893 | 12 | 88.0% |
| Consulting Fee | $97,166 | 31 | 8.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,644 | 10 | 2.8% |
| Honoraria | $2,500 | 1 | 0.2% |
| Travel and Lodging | $815.66 | 5 | 0.1% |
| Food and Beverage | $752.13 | 12 | 0.1% |
| Education | $45.81 | 3 | 0.0% |
Payments by Type
Research
$969,893
12 transactions
General
$131,923
62 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $564,382 | 3 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $400,024 | 2 | $0 (2017) |
| PFIZER INC. | $46,271 | 18 | $0 (2023) |
| Janssen Research & Development, LLC | $22,001 | 15 | $0 (2022) |
| SANOFI US SERVICES INC. | $17,942 | 5 | $0 (2019) |
| Insmed, Inc. | $13,440 | 7 | $0 (2024) |
| LEO Pharma AS | $12,917 | 5 | $0 (2020) |
| SANOFI-AVENTIS U.S. LLC | $10,759 | 14 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $7,650 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $4,500 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,240 | 1 | Insmed, Inc. ($2,240) |
| 2023 | $10,091 | 7 | Insmed, Inc. ($5,440) |
| 2022 | $13,463 | 8 | PFIZER INC. ($5,793) |
| 2021 | $21,462 | 6 | PFIZER INC. ($17,262) |
| 2020 | $17,903 | 4 | PFIZER INC. ($12,236) |
| 2019 | $56,488 | 14 | Bausch Health US, LLC ($30,000) |
| 2018 | $552,678 | 12 | Bausch Health US, LLC ($534,382) |
| 2017 | $427,491 | 22 | Valeant Pharmaceuticals North America LLC ($400,024) |
All Payment Transactions
74 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
| 11/18/2023 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,560.00 | General |
| 07/31/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $120.90 | General |
| Category: Respiratory | ||||||
| 06/30/2023 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $960.00 | General |
| 05/01/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 03/07/2023 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 02/15/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 01/02/2023 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 12/26/2022 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $3,420.00 | General |
| 10/24/2022 | PFIZER INC. | EUCRISA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,700.00 | General |
| Category: DERMATOLOGY | ||||||
| 10/24/2022 | PFIZER INC. | CIBINQO (Drug) | Education | In-kind items and services | $15.27 | General |
| Category: Inflammation & Immunology | ||||||
| 09/02/2022 | PFIZER INC. | EUCRISA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: CRISABOROLE CLINICAL PUBLICATION PROGRAM • Category: DERMATOLOGY | ||||||
| 05/12/2022 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 05/04/2022 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $410.00 | General |
| 03/07/2022 | PFIZER INC. | EUCRISA (Drug) | Consulting Fee | Cash or cash equivalent | $1,748.00 | General |
| Category: DERMATOLOGY | ||||||
| 01/28/2022 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 11/15/2021 | PFIZER INC. | EUCRISA (Drug) | Consulting Fee | Cash or cash equivalent | $4,370.00 | General |
| Category: DERMATOLOGY | ||||||
| 07/05/2021 | PFIZER INC. | EUCRISA (Drug) | Consulting Fee | Cash or cash equivalent | $437.00 | General |
| Category: DERMATOLOGY | ||||||
| 06/21/2021 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| 05/17/2021 | PFIZER INC. | EUCRISA (Drug) | Consulting Fee | Cash or cash equivalent | $8,958.50 | General |
| Category: DERMATOLOGY | ||||||
| 05/17/2021 | PFIZER INC. | EUCRISA (Drug) | Consulting Fee | Cash or cash equivalent | $3,496.00 | General |
| Category: DERMATOLOGY | ||||||
| 02/22/2021 | Insmed, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,920.00 | General |
| 12/09/2020 | LEO Pharma AS | — | Consulting Fee | Cash or cash equivalent | $5,187.50 | General |
| 10/20/2020 | LEO Pharma AS | — | Consulting Fee | Cash or cash equivalent | $479.40 | General |
| 06/01/2020 | PFIZER INC. | EUCRISA (Drug) | Consulting Fee | Cash or cash equivalent | $2,622.00 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 2017-2753 Margolis | Bausch Health US, LLC | $564,382 | 3 |
| IIS 2017-2753 Margolis | Valeant Pharmaceuticals North America LLC | $400,000 | 1 |
| PROTOPIC APPLES | LEO Pharma AS | $4,000 | 2 |
| Design, Validation and Scoring of the Atopic Dermatitis Control Tool (ADCT) | SANOFI-AVENTIS U.S. LLC | $972.40 | 2 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| Patient-reported Disease Burden in Adults with Atopic Dermatitis in the Clinical Practice Setting and Impact of Inadequately Controlled Disease: A US Cross-sectional Study | SANOFI-AVENTIS U.S. LLC | $184.88 | 2 |
| Epi AWARE | SANOFI-AVENTIS U.S. LLC | $24.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 81 | 109 | $13,413 | $5,104 |
| 2022 | 6 | 169 | 208 | $31,481 | $9,411 |
| 2021 | 5 | 142 | 168 | $25,158 | $8,387 |
| 2020 | 5 | 120 | 144 | $17,696 | $4,778 |
Total Patients
512
Total Services
629
Medicare Billing
$27,680
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 58 | 81 | $7,673 | $3,923 | 51.1% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 23 | 28 | $5,740 | $1,180 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 81 | 113 | $10,639 | $5,188 | 48.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 28 | 32 | $6,560 | $1,300 | 19.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 22 | 22 | $3,215 | $1,194 | 37.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2022 | 15 | 17 | $7,837 | $922.83 | 11.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 11 | $1,540 | $493.44 | 32.0% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2022 | 12 | 13 | $1,690 | $312.33 | 18.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 72 | 90 | $8,370 | $4,668 | 55.8% |
| 17000 | Destruction of skin growth | Facility | 2021 | 25 | 29 | $5,945 | $1,330 | 22.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 17 | $2,380 | $1,316 | 55.3% |
| 17110 | Destruction of up to 14 skin growths | Facility | 2021 | 13 | 13 | $5,993 | $686.52 | 11.5% |
| 11102 | Tangential biopsy of single skin lesion | Facility | 2021 | 17 | 19 | $2,470 | $387.12 | 15.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 43 | 61 | $5,673 | $2,258 | 39.8% |
| 17000 | Destruction of skin growth | Facility | 2020 | 17 | 20 | $4,100 | $806.69 | 19.7% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 38 | 41 | $1,312 | $670.80 | 51.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 11 | 11 | $1,540 | $659.50 | 42.8% |
| 17110 | Destruction of up to 14 skin growths | Facility | 2020 | 11 | 11 | $5,071 | $382.68 | 7.5% |
About Dr. David Margolis, MD
Dr. David Margolis, MD is a Dermatology healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740205327.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Margolis, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $2,240 received in 2024. These payments were reported across 74 transactions from 13 companies. The most common payment nature is "" ($969,893).
As a Medicare-enrolled provider, Margolis has provided services to 512 Medicare beneficiaries, totaling 629 services with total Medicare billing of $27,680. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Philadelphia, PA
- Active Since 07/13/2006
- Last Updated 08/20/2012
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1740205327
Products in Payments
- SILIQ (Drug) $964,382
- EUCRISA (Drug) $33,487
- DUPIXENT (Drug) $28,701
- PROTOPIC (Drug) $7,250
- GUSELKUMAB (Biological) $5,876
- Tremfya (Drug) $2,160
- SIRUKUMAB (Biological) $1,080
- TEZSPIRE (Biological) $120.90
- CIBINQO (Drug) $45.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Philadelphia
Stephen Hess, Md, MD
Dermatology — Payments: $1.8M
Dermatology $1.8M
Joel Gelfand, Md, MD
Dermatology — Payments: $787,044
Dermatology $787,044
Victoria Werth, Md, MD
Dermatology — Payments: $555,094
Dermatology $555,094
Dr. Harold Farber, M.d,, M.D,
Dermatology — Payments: $484,640
Dermatology $484,640
Dr. Lawrence Parish, Md, MD
Dermatology — Payments: $406,273
Dermatology $406,273
Dr. Jules Lipoff, Md, MD
Dermatology — Payments: $294,407
Dermatology $294,407